Trial Profile
Pilot Study with Treatment of Short Bowel Syndrome Patients with dipeptidyl-peptidase 4 inhibitor, Sitagliptin (Januvia)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Short bowel syndrome
- Focus Therapeutic Use
- 23 Mar 2019 Status changed from recruiting to discontinued.
- 05 Jan 2015 New trial record